• CAPE Derivatives Target Mitochondrial Metabolism in HCC Ther

  2026-08-01

  This study introduces a novel caffeic acid phenethyl ester (CAPE) derivative, WX006, as a potent anti-hepatocellular carcinoma agent. By targeting mitochondrial respiration and disrupting metal ion homeostasis, WX006 demonstrates robust antitumor effects and highlights new strategies for metabolic cancer therapy.

• Tolazoline (SKU A8991): Reliable α2-Adrenergic Antagonism in

  2026-07-31

  This article addresses real-world laboratory challenges in cell viability, airway smooth muscle, and islet function assays, demonstrating how Tolazoline (SKU A8991) offers reproducible and well-characterized solutions for dissecting α2-adrenergic signaling. Scientific evidence and workflow optimization tips are integrated, supporting biomedical researchers in protocol design and data interpretation.

• LGK-974: Translational Leverage of PORCN Inhibition in Wnt-D

  2026-07-31

  Explore how LGK-974, a potent PORCN inhibitor, enables new strategies for dissecting Wnt signaling and advancing pancreatic cancer research. This article uniquely bridges mechanistic insight with practical assay design, highlighting translational opportunities beyond current literature.

• G418 Sulfate (Geneticin): Selection, Antiviral, and Troubles

  2026-07-30

  G418 Sulfate (Geneticin) offers precise selection for neomycin resistance and potent antiviral action against Dengue virus serotype 2. This guide details optimized experimental workflows, cross-domain applications, and actionable troubleshooting strategies for advanced cell engineering and virology research.

• Cyanine 5-dCTP: Advancing Fluorescent DNA Labeling Precision

  2026-07-30

  Cyanine 5-dCTP empowers researchers to achieve high-yield, low-error fluorescent DNA labeling in enzymatic synthesis, unlocking new potential for nucleic acid detection and fluorescence microscopy. Leveraging insights from ordered DNA nanostructures, this guide details optimized protocols, troubleshooting tips, and advanced use-cases that set APExBIO’s Cy5-dCTP apart.

• Spatial Transcriptomics Uncovers Cortical Lewy Pathology Mec

  2026-07-29

  This study applies spatial transcriptomics to distinguish molecular changes in cortical neurons affected by Lewy pathology in Parkinson’s disease. The findings reveal selective vulnerability among excitatory neuron subtypes and define a conserved gene expression dysfunction signature, advancing our understanding of neurodegenerative mechanisms and potential research directions.

• Evaluating Fumagillin’s Efficacy Against Azumiobodo hoyamush

  2026-07-29

  This study systematically assessed a broad panel of antiprotozoal agents, including Fumagillin, for their ability to inhibit Azumiobodo hoyamushi, the causative agent of soft tunic syndrome in Halocynthia roretzi. The research provides quantitative efficacy data that inform both aquatic disease management and the broader application of methionine aminopeptidase-2 inhibitors in parasitology and related fields.

• ALOX5 Deficiency Drives Ferroptosis Escape in Bladder Cancer

  2026-07-28

  This study reveals that deficiency of ALOX5, regulated by EGR1, is a central driver of ferroptosis resistance in advanced bladder cancer. The findings identify ALOX5 as both a therapeutic target and a prognostic biomarker, with implications for overcoming therapy resistance and improving patient outcomes.

• Gemcitabine HCl: Protocol Innovations for Pancreatic Cancer

  2026-07-28

  Gemcitabine HCl sets the benchmark for DNA replication inhibition and apoptosis induction in pancreatic cancer research. Discover how multianimal MRI and optimized protocols elevate experimental throughput, reproducibility, and data quality for tumor growth suppression studies.

• Midecamycin: Strategic Insights for Translational Researcher

  2026-07-27

  This thought-leadership article delivers a strategic, mechanistic, and translational perspective on Midecamycin, a 16-membered acetoxy-substituted macrolide antibiotic. It synthesizes current biological rationale, experimental best practices, comparative landscape analysis, and clinical implications—while providing actionable protocol guidance and a forward-looking vision for antibiotic research. The discussion is anchored in the latest evidence, including pharmacokinetic insights from related macrolide studies, and uniquely escalates the dialogue beyond standard product pages.

• DRB: Unleashing Precision in Transcriptional Control for Tra

  2026-07-27

  Explore how 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) is reshaping the landscape of transcriptional elongation inhibition, cell fate engineering, and antiviral research. This article navigates the mechanistic underpinnings and translational opportunities of DRB, interweaving recent advances in RNA biology and kinase signaling with actionable guidance for translational scientists.

• Combinational Targeting of eIF4F, AKT1, and EZH2 in BRAFV600

  2026-07-26

  This study demonstrates that jointly inhibiting the eIF4F complex, AKT1, and EZH2 overcomes resistance to targeted therapies in BRAFV600E mutant A375 melanoma cells. The findings reveal critical adaptive signaling interactions and suggest multi-targeted regimens can improve anticancer outcomes in resistant melanoma.

• Necrostatin-1: Dissecting Necroptosis in Host-Pathogen Model

  2026-07-25

  Explore how Necrostatin-1, a potent RIP1 kinase inhibitor, empowers advanced necroptosis assays and translational immune research. This article uniquely bridges cell death mechanisms with emerging host-pathogen insights, providing in-depth guidance for innovative experimental design.

• Isoprinosine Applications: Immunotherapy and Viral Inhibitio

  2026-07-24

  Isoprinosine (inosine pranobex) from APExBIO empowers researchers with a robust, reproducible platform for studying viral inhibition and immunomodulation, including herpesvirus biology and respiratory infection models. This article delivers actionable workflow protocols, troubleshooting tips, and a translational bridge to recent breakthroughs in viral egress mechanisms.

• Vernakalant Hydrochloride: Translating Atrial-Selective Inno

  2026-07-24

  This thought-leadership article explores Vernakalant Hydrochloride (RSD1235) as a paradigm-shifting, atrial-selective antiarrhythmic for rapid atrial fibrillation conversion. Integrating mechanistic insights with translational strategies, we bridge the gap between ion channel pharmacology and real-world clinical research, offering actionable guidance for researchers aiming to accelerate the journey from bench to bedside.

461 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page